Biotech company Alexion is paying $8.4 Billion to acquire Synageva, nearly double the target's market cap. While the terms of the acquisition are fascinating, the proposition evokes a philosophical quandary: Why would a company pay such a large premium to acquire a firm with one drug that treats a genetic disease affecting 3,000 people? The answer: Business.
Synageva's product hasn't hit the market yet, but is in late stage development. The process of getting a drug to late stage development is incredibly difficult, hence the premium. Still, how can Alexion expect to make their money back if the drug can only help 3,000 people? The answer: Business.
Still, at a certain point, one would expect some type of balance between big pharma companies stronghold on insurance companies. Structurally, an equitable answer is unlikely to come to fruition any time soon. Biotech is one of the few industries experiencing rapid and meaningful innovation. It should come as no surprise that valuations continue to be stretched in the $IBB. Biotech offers investors safety from forex fluctuations while adding exposure to innovation and consolidation.
The 124% premium wets the appetite's of investors further. The trend of market consolidation mixed with cheap financing and rapid innovation reminds investors of how profitable small cap buyouts can be. While valuations may be stretched and the pharmaceutical industry as a whole can be extremely speculative, opportunities are still abundant. Biotech is experiencing growth, something lacking across the board.
Synageva's product hasn't hit the market yet, but is in late stage development. The process of getting a drug to late stage development is incredibly difficult, hence the premium. Still, how can Alexion expect to make their money back if the drug can only help 3,000 people? The answer: Business.
Since this drug is the only treatment available, insurance companies are forced to pay for the drugs, regardless of price. This is fantastic for the 3,000 people affected with the disease. A company found an opportunity to fill a market need and capitalized on it. Joseph Schwartz of Leernik Partners estimates Synageva could charge about $350K per patient annually for the drug. Society flips the bill, as insurance costs skyrocket.
However, on the flip side, society benefits greatly. Pharmaceutical companies need large incentives to pour money into the R&D necessary to create life saving drugs. Without these incentives there would be no drugs and no innovation. Regulators exacerbate the process further by offering incentive to companies like expanded periods of market exclusivity.Still, at a certain point, one would expect some type of balance between big pharma companies stronghold on insurance companies. Structurally, an equitable answer is unlikely to come to fruition any time soon. Biotech is one of the few industries experiencing rapid and meaningful innovation. It should come as no surprise that valuations continue to be stretched in the $IBB. Biotech offers investors safety from forex fluctuations while adding exposure to innovation and consolidation.
The 124% premium wets the appetite's of investors further. The trend of market consolidation mixed with cheap financing and rapid innovation reminds investors of how profitable small cap buyouts can be. While valuations may be stretched and the pharmaceutical industry as a whole can be extremely speculative, opportunities are still abundant. Biotech is experiencing growth, something lacking across the board.